Form 4: Elevance Health Executive Kendrick Charles Morgan JR. Reports Stock Transactions

Elevance Health's EVP & President, Commercial, Kendrick Charles Morgan JR., reports acquisition and disposal of company stock and derivative securities.

Summary

• Kendrick Charles Morgan JR., an EVP & President at Elevance Health, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On March 3, 2025, Morgan acquired 2,845 restricted share units and 3,686 performance-based restricted share units, both at $0.
• Also on March 3, 2025, 2,221 shares were withheld for tax liability at a price of $395.5.
• On March 5, 2025, Morgan disposed of 3,504 shares at $396.3.
• Following these transactions, Morgan directly owns 10,116 shares of common stock.
• Morgan also acquired an option to purchase 10,828 shares of common stock at $395.5, exercisable in three annual installments starting March 3, 2026.
• The balance includes 22.89 shares acquired on December 20, 2024, through a dividend reinvestment plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are a mix of acquisitions and disposals, which are typical for executive stock management. There's no clear indication of overwhelmingly positive or negative sentiment based solely on this form.

Positives

• The acquisition of restricted share units and performance-based restricted share units indicates confidence in the company's future performance.
• The acquisition of an option to purchase 10,828 shares suggests a long-term commitment to the company.

Negatives

• The disposal of 3,504 shares on March 5, 2025, could be interpreted negatively, although it may be for personal financial reasons.

Risks

• Executive stock transactions can sometimes be driven by factors unrelated to company performance, making it difficult to interpret the true implications.
• Significant stock sales by executives could potentially create negative market sentiment.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedule of restricted stock units and the exercisability of stock options suggest a multi-year alignment of the executive's interests with the company's performance.

Industry Context

Executive stock transactions are common in publicly traded companies and are often scrutinized by investors for insights into management's confidence in the company's prospects. These transactions are a normal part of executive compensation and wealth management.

Comparison to Industry Standards

• Executive compensation packages, including stock options and restricted stock units, are standard practice among large healthcare companies like UnitedHealth Group (UNH), CVS Health (CVS), and Cigna (CI).
• The vesting schedules and exercise prices are generally in line with industry norms for incentivizing long-term performance.
• The size of the transactions is typical for an executive at Morgan's level within a company the size of Elevance Health.

Stakeholder Impact

• The transactions could have a minor impact on shareholder sentiment, depending on how they are interpreted.
• The vesting of restricted stock units and the exercisability of stock options align the executive's interests with those of the shareholders.

Key Dates